Abhijit R

  • Cancer Vaccines Market Industry Growth, Trends, Outlook, and Forecast, 2018 to 2026

    Cancer is the second leading cause of morbidity and mortality worldwide. Major cause of cancer is gene mutation and rarely due to inherited genes. On the basis of the type of cell it initiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias, brain tumors, and sarcomas. According to World Health Organization (WHO), 2017, nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income countries. Moreover, it is projected that for next two decades, 70% of new cases are expected to be diagnosed globally. Advent of cancer vaccines can significantly reduce this numbers and lead a cancer-free life for the global population.

    Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC (PPD), in order to conduct its first-in-human clinical trial for its cancer vaccine for metastatic colorectal cancer.

    Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1209

    Furthermore, BioNTech developed RNA vaccines for mutations caused due to cancer. RNA vaccine exposes cancer cell to antigen, which is recognized by the immune system. On the other hand, Scancell’s DNA vaccine forces cancerous cell to express two antigens – gp100 and TRP-2 stimulating a strong T cell response.

    In 2017, Jonsson Comprehensive Cancer Center and the Brain Tumor Center at the University of California Los Angeles (UCLA), was designated a Specialized Program of Research Excellence (SPORE) by the National Cancer Institute. The program is expected to support research into prevention, detection, and treatment of cancers and will promote co-operation among scientist in different disciplines, and also help to translate basic research from laboratories to clinical trials more quickly and effectively. Such recognition by national organizations is expected to support research in cancer vaccines.

    According to a research from University of Pittsburgh School of Medicine, in 2017, a high dose flu vaccine can be used to treat people aged between 54–64 years with chronic condition such as heart disease, lung disease, diabetes, and cancer. The study is recommended for clinical trials in geriatric population.

    Also, in 2017, Swiss Biotech, developed VXM01 — an attenuated bacterial vaccine modified to express vascular endothelial growth factor receptor-2 (VEGFR2), stimulates cytotoxic (killer) T cells, which will destroy cells in the vasculature feeding tumor and allow greater infiltration of immune cells. This vaccine is expected to be used for treatment in colorectal cancer and glioblastoma.

    Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1209

    In August 2017, Imugene Limited announced the entry of its anti-cancer vaccine, HER-Vaxx for gastric cancer in 1b/2 clinical study and the phase 2 is expected to start soon.

    Global Cancer Vaccines Market Taxonomy:

    By Product Type:

    Preventive cancer vaccines

    Therapeutic cancer vaccines

    By Technology:

    Subunit Vaccines

    Live Attenuated Vaccines

    Conjugate Vaccines

    Inactivated Vaccines

    Recombinant Vector Vaccines

    Viral Vector And DNA Cancer Vaccines

    Others

    By Application:

    Cervical cancer

    Prostate cancer

    Others

    According to WHO, in 2015, about 8.8 million people died from cancer. Moreover, tobacco related cancers was responsible for 22% deaths, lung cancer accounted for 1.69 million deaths, liver cancer led to 788,000 deaths. Colorectal, stomach, and breast cancer are estimated to cause 774,000, 754,000, and 571,000 deaths, worldwide. Increasing prevalence is a major driving factor to fuel growth of the cancer vaccines market.

    Key players in the global cancer vaccines market include, Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

    Browse the Full Report Here: https://www.coherentmarketinsights.com/ongoing-insight/cancer-vaccines-market-1209

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Biologics Market Industry Growth, Size, Share, Outlook, and Forecast, 2018 to 2026

    Biologics market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

    Furthermore, the biologics market revenue is growing because of increasing number of Food and Drug Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017 US FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

    Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

    Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2663

    Important Features that are under offering & key highlights of the report :

    1) Can we add or profiled new company as per our need? Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by research team depending upon the difficulty of survey.

    ** Data availability will be confirmed by research in case of privately held company. Upto 3 players can be added at no added cost.

    2) What all regional segmentation covered? Can specific country of interest be added? Currently, research report gives special attention and focus on following regions: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)

    ** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

    3) Can inclusion of additional Segmentation / Market breakdown is possible? Yes, inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However a detailed requirement needs to be shared with our research before giving final confirmation to client.

    Receive Sample on Biologics Research: https://www.coherentmarketinsights.com/insight/request-sample/2663

    Competitive Analysis:

    The research report on Biologics Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2026. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

    The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. The report classifies the market into different segments based on technique, application and end-user. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2663

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Stem Cell Therapy Market Industry Growth, Size, Share, Trends, and Analysis 2018 to 2026

    Stem cells are divided into two major classes; pluripotent and multipotent. Pluripotent cells are stem replicating cells which are derived from the embryo or fetal tissues. The pluripotent stem cells facilitate the development of cells and tissues in three primary germ layers such as mesoderm, ectoderm, and endoderm.

    Expansion of facilities related to stem cell therapies is expected to propel growth of the stem cell therapy market. For instance, in January 2018, the University of Florida, U.S. launched the Center for Regenerative Medicine that is focused on development of stem cell therapies for the treatment of damaged tissue and organ. The Centre for Regenerative Medicines is divided into two segments such as focus groups and shared services. Focus groups such as research and development activities for stem cell therapies; and the shared services segment provides technical resources related to stem cell therapies.

    Request Sample Copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2848

    Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market. For instance, in May 2018, Procella Therapeutics and Smartwise Medtech Company collaborated with AstraZeneca Pharmaceuticals. Under this collaboration, AstraZeneca was able to utilize Procella Therapeutics’ stem cell technology for development of stem cell therapies in cardiovascular diseases.

    Stem cell banks facilitate extraction, processing of stem cells, and storage of stem cells for future use. Increasing launches of stem cell banks is expected to boost the stem cell therapy market growth. For instance, in January 2018, Lifecell Biotechnology launched a stem cell bank in India, which preserves and provides umbilical cord stem cells for stem cell transplantation. In a stem cell transplantation therapy damaged, diseased cell or tissues are replaced or repaired by using stem cells. Hence, stem cell banking is expected to support the stem cell therapy market growth.

    Increasing number of approvals from regulatory authorities are expected to drive growth of the global stem cell therapy market. For instance, in March 2018, TiGenix NV and Takeda Pharmaceuticals received central marketing authorization from the European Commission to market Alofisel (an allogeneic stem cell therapy) in Europe. This therapy is used for the treatment of complex perianal fistulas in adult patients.

    Key players in the stem cell therapy market are focused on launching new products in order to strengthen their position in the market. For instance, in November 2015, Osiris Therapeutics, Inc. launched its new product Stravix. Stravix is a viable cryopreserved human placental tissue, and is a used in soft tissue repair therapies.

    Browse the Full Report at https://www.coherentmarketinsights.com/market-insight/stem-cell-therapy-market-2848

    Moreover, increasing research and development activities around the world are expected to propel the stem cell therapy market growth. For instance, in December 2017, Mayo Clinic initiated the clinical phase I study on safety and feasibility of mesenchymal stem cells therapy in patients with recent intracerebral hemorrhage. This therapy is used for treating acute spontaneous hemorrhagic stroke. The study is expected to complete in December 2020.

    Furthermore, In October 2017, University of California, San Francisco, U.S. initiated the clinical phase I study to evaluate the safety and efficacy of “In Utero Hematopoietic Stem Cell Transplantation” for treatment of fetuses with alpha thalassemia major. This is a blood disorder which reduces production of hemoglobin. The study is expected to complete in February 2024.

    Major players operating in the global stem cell therapy market include Osiris Therapeutics, Inc. Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc., and Fibrocell Science, Inc.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2848

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Urinary Incontinence Treatment Devices Market – Size, Share, Outlook, and Analysis, 2019-2026

    Urinary Incontinence means losing control of bladder, due to which there is an involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost and due to this, a person urinates even when they don’t want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra don’t work in the way they should, resulting in leak-out of urine. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.

    Request Sample Copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2892

    Extensive research and development by major players is expected to support global urinary incontinence treatment devices market growth over the forecast period. Key factors that boost the market growth are rise in surgical treatments of urinary incontinence due to increase in chronic conditions (kidney stones, pregnancy, paralysis, and neuromuscular injury) that have developed the need for innovating urinary catheters. The global urinary incontinence treatment devices market growth is driven by high incidence and increase in prevalence of urinary incontinence across the globe and increasing product approvals by regulatory authorities. According to integrated care for older people (ICOPE) guidelines by World Health Organization (WHO), a population based study was carried out in 2017 an ‘Evidence profile: urinary incontinence’ in U.S. and Nordic countries (Denmark, Norway, Sweden) It is reported that the prevalence of urinary incontinence was ranging from 9.9% to 36.1% and was high in older women than the older men in.

    Due to advancement in technology, leading players are manufacturing had come up with few recent launches for urinary incontinence products such as ‘Advance XP’ Male Sling System by Boston Scientific launched sling for male stress urinary incontinence in February 2019, ‘DFree’ first wearable device for urinary incontinence was launched by Triple W in December 2018 in U.S. and people are widely adopting such products. Furthermore, ‘INNOVO’, a transcutaneous electrical stimulator by Atlantic Therapeutics received an approval from the U.S. Food and drug Administration (FDA) in 2018, which is used for treatment of urinary incontinence types such as stress, urge & mixed urinary incontinence in both women and men of all ages. These factors are expected to support global urinary incontinence treatment devices market growth over the forecast period.

    According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S. Boston Scientific Corporation formed an agreement with Endo International Plc to acquire the American Medical Systems urology portfolio in 2015 which had products such as AMS 800 Urinary Control System for male stress urinary incontinence, which restores continence with an occlusive cuff and a corresponding pump that is controlled by patients. Moreover, leading players in the market are focusing on continues research for urinary incontinence and have introduced products to manage the urinary incontinence. For instance, B. Braun Melsungen AG offers products Diveen device for women and Urimed product portfolio for men. According to National Center for Biotechnology Information (NCBI) in article “Urinary incontinence in postmenopausal women (2019)” it was reported that there is rise in incidence of various diseases such as (Parkinson's disease, diabetes, multiple sclerosis etc.) which may lead to increased prevalence of urinary incontinence in males/females, which is expected to drive the global urinary incontinence treatment devices market growth.

    Browse the Full Report Here: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892

    Global Urinary Incontinence Treatment Devices Market Taxonomy

    By Product:

    Urinary Catheters

    Electrical Stimulation Devices

    Artificial Urinary Sphincters

    Wearable devices

    Slings

    Male Slings

    Female Slings

    Other Devices

    By Category:

    Internal Urinary Incontinence Devices

    External Urinary Incontinence Devices

    By Incontinence Type:

    Stress Incontinence

    Urge Incontinence

    Overflow Incontinence

    Functional Incontinence

    By End User:

    Clinics

    Hospitals

    Ambulatory surgical centers

    Others

    By Region:

    North America

    Latin America

    Europe

    Asia Pacific

    Middle East

    Africa

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2892

    Some of the major players operating in the global urinary incontinence treatment devices market include Boston Scientific Corporation, Agency for Medical Innovations (A.M.I.) GmbH, B. Braun Melsungen AG, Coloplast Group, Atlantic Therapeutics, Hollister Incorporated, Medtronic plc, ZSI Surgical Implants S.R.L., Promedon Group, Ethicon US, Teleflex Incorporated, and C. R. Bard, Inc.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Gel Stent Market Industry Growth, Size, Share, Outlook, and Forecast | 2018-2026

    Stent is a small expandable tube used for the treatment of narrowed arteries. It is used to prevent bursting of arteries and improve blood flow of weak arteries. Soft gelatin is used for the preparation of gel stent. When gel stent is injected, it gets hydrated and drains the aqueous humor in the sub-conjunctival space, which lowers the intraocular pressure. This procedure is minimally invasive.

    Rising population above the age of 40 is a major factor driving growth of the market. For instance in 2017, 2.7 million out of 3 million Americans are suffering with glaucoma were aged 40 and older. This is attributed to high chances of people aged 40 and above suffering from miosis, in which excessive contraction of eye increase in the elder population. Glaucoma is one of the leading cause for blindness. Increasing demand for minimally invasive procedures and increasing incidences of glaucoma are other factors that are expected to drive growth of the global gel stent market over the forecast period. According to Glaucoma Research Society in U.S. in 2017, more than 120,000 are blind from glaucoma.

    Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2404

    However, high cost of the gel stent, lack of availability of healthcare professionals and lack of awareness regarding the technique are factors that hinder growth of the gel stent market.

    On the basis of geography, the global gel stent market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the gel stent market, followed by Europe during the forecast period. The U.S. holds dominant position in the market in this region due to continuous technological advancements and developed healthcare infrastructure.

    According to American Glaucoma Society, glaucoma is the second leading cause of blindness in the U.S. and globally. In the U.S, over 3 million people suffer from glaucoma while only 50% are aware of the diagnosis. In 2016, over 120,000 people in the U.S. suffered from blindness due to glaucoma.

    According to the World Health Organization (WHO), Asians have more chances of suffering from close angle glaucoma while people from Europe or Africa are more likely to suffer from primary open angle glaucoma. According to WHO, In South India, glaucoma prevalence is 2.6%. In Africa, the prevalence of glaucoma is 1–2%, but can rise to about 10% in the Caribbean.

    Purchase a copy of Gel Stent Market Research: https://www.coherentmarketinsights.com/insight/buy-now/2404

    Gel Stent Market – Taxonomy

    On the basis of end user:

    Eye Research Institutes

    Eye Clinics

    Hospitals

    On the basis of geography:

    North America

    Latin America

    Europe

    Asia Pacific

    Middle East

    Africa

    Key players are focusing on research and development, in order to develop technologically advanced products and enhance their product portfolio. The XEN (Allergan) received approval from the U.S. Food and Drug Administration (FDA) in November 2016 and launched in the U.S. in early 2017. Major players operating in the global gel stent market include Allergan, Alcon, Innfocus and Glaukos Corp.

    Browse the Full Report Here: https://www.coherentmarketinsights.com/ongoing-insight/gel-stent-market-2404

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Surgical Drapes and Gowns Market - Industry, Size, Share, Trends, and Forecast 2018-2026

    Surgical drapes are used in surgical procedures, which prevents the contact of the physicians from unwanted surfaces to prevent contamination and infection risks. It also prevents any kind of contamination and thus maintains sterility. Drapes acts as physical barrier during the surgery against microbes and are resistant to heat. Surgical gowns are worn over in the operating room to perform surgeries. Its characteristics are similar to that of surgical drape. Surgical drapes and gowns are produced according to the type of surgery. These are either disposable or non-disposable. They are generally made from tightly woven fabric, cotton, and polyester, which may or may not be chemically treated.

    Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2818

    Factors such as active involvement and growth strategies adopted by key players in the market is expected to influence the global surgical drapes and gowns market growth positively. Furthermore, regulatory support and initiatives towards hygiene and prevention of infectious diseases are expected to impact positively on the global surgical drapes and gowns market growth.

    For instance, in December 2018, Drugs Technical Advisory Board (DTAB) of India, added surgical gowns, surgical drapes, and incision drapes to the list of notified medical devices, as proposed by the Central Drug Standards Control Organization (CDSCO). Moreover, in April 2018, Medline set up a new manufacturing facility for surgical trays that includes drapes and gowns. Hence, these factors are expected to boost the global surgical drapes and gowns market growth.

    Key players are indulged in obtaining approvals for their products from regulatory bodies which is expected to impel the global surgical drapes and gowns market growth. For instance, in 2017, Anhui Medpurest Medical Technology Co., Ltd. received an U.S. Food & Drug Administration (FDA) approval for Poly-Reinforced Specialty Surgical Gown, Fabric-Reinforced Surgical Gowns, and Non-Reinforced Surgical Gowns. These are disposable, sterile gowns that prevents the risk of infections.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2818

    Furthermore, the global surgical drape and gown market growth is expected to boost over the forecast period, owing to increasing product launches. For instance, in 2015, Lohmann & Rauscher introduced Sentinex Mini Thermo Poncho that is worn by the operating room staff and as well as by the patients. Its characteristics include low lint, low microbe and air permeability, which prevents any kind of contamination and maintains sterility in the environment.

    Moreover, key players are also focused on participating in conferences and events, which is expected to drive the global surgical drapes and gowns market growth. For instance, in May 2019, Mölnlycke Healthcare AB participated in the event European Operating Nurses Association (EORNA) congress, which was held in the Netherlands. The focus of the event was on quality management and hygiene of patients and staff in operating room. The company showcased its product in the event to increase awareness among people.

    Major players operating in the global surgical drapes and gowns market include 3M, Halyard Health, Medline, Thermo Fisher Scientific Inc., Steril Medical, Alpha Pro Tec, Mölnlycke Health Care AB, Anhui Medpurest Medical Technology Co., Ltd., Lohmann & Rauscher, and Vygon

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2818

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Ferrous Fumarate Market – Industry Size, Share, Trends, and Forecast 2019-2027

    Ferrous fumarate is the iron (II) salt of fumaric acid used for the prevention and treatment of iron-deficiency anemias. It is used as a dietary supplement and its administration results in elevation of serum iron concentration, which is then assimilated into hemoglobin. Hemoglobin carries oxygen through blood to tissues and organs. Ferrous fumarate is used for the treatment of thalassemia, iron deficiency anemia, fatigue, and anemia. It is also used for diagnostic assessment.

    Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2841

    Market Dynamics

    Increasing prevalence of anemia and thalassemia is expected to boost growth of the global ferrous fumarate market. Anemia is a condition characterized by lack of red blood cells to carry adequate oxygen to the body's tissues. Women in the childbearing years are highly vulnerable to anemia and iron-deficiency. Ferrous fumarate tablets can be consumed orally and are easy to swallow. These tablets can be crushed or chewed as they are almost tasteless. It acts as an iron supplement to treat or prevent low blood levels of iron.

    However, there are many restrictions in use of ferrous fumarate. Ferrous fumarate is not recommended to those suffering from liver or kidney disease and porphyria. Consuming ferrous fumarate is also associated with some side effects such as constipation, black stool, stomach pain, abdominal bloating, flatulence, and abdominal pain.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2841

    Market Outlook

    Among regions, North America is expected to hold dominant position in the global ferrous fumarate market over the forecast period. This is majorly attributed to presence of key pharmaceutical companies in the region. Asia Pacific is expected to witness the fastest growth rate in the market, owing to increasing prevalence of anemia in the region. Moreover, significant growth in the pharmaceutical industry in economies such as India and China is also expected to contribute to the global market size. Key players in the market can focus on expanding their business in emerging regions such as Africa and Middle East to enhance their market share. Africa, South East Asia, and the Eastern Mediterranean are the regions with high prevalence of anemia

    Key Players

    Some of the manufacturers operating in the global ferrous fumarate market include, Vifom Pharma, Ironwood Pharmaceuticals, Galenica group, Allied Biochem Pvt. Ltd., Lonye Technology Limited, Shreeji Industries, and Henan Sinotech Import & Export Corporation.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2841

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Medical Implants Sterile Packaging Market 2017 | Industry Growth, Size, Outlook, 2025

    Thermoform Engineered Quality has developed a new solution—TEQpropylene that is intended to reduce sterile packaging costs and harmful environmental impacts. The strength, sustainability, and clarity improvements of TEQpropylene offers cost-effective packaging. Moreover, pouches made by Tyvek are used for packaging various sterilized medical devices, particularly those devices that are low profile and light weight. Sterilization pouches made by Tyvek are used in outpatient surgical centers and in house sterilization of surgical instruments, owing to its resistance to microbial penetration. Such resistance aid in retaining sterility of contents in pouches until opened. Moreover, Tyvek pouches provide superior puncture resistance and tear strength as compared to medical-grade papers, which is a major factor contributing to increase in demand for its use in sterilization of medical devices.

    The global medical implants sterile packaging industry over the last few decades have observed a notable growth due to significant increase in the number of implant products. Medical implants sterile packaging has been widely used in the packaging of joint, spinal, and support implants, owing to anti contaminant and high-performance factors. Sterile packaging plays a vital role in the life-saving pharmaceuticals drugs and medical devices.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/995

    However, there are other implants, which deliver medication, provide support to tissues and organs, and monitor body functions. Clamshell pack is one of the fastest growing segments in the medical implants sterile packaging market. Clamshell packaging has numerous advantages with respect to appearance, portability, and convenience. It is mainly used to pack various medical and surgical appliances and instruments.

    According to American Association of Oral and Maxillofacial Surgeons, in 2014, around 69% of adults aged between 35 and 44 have lost at least one permanent tooth due to unsuccessful root canal, to an accident or by tooth decay. Thus, there is a rise in the practice of dental implants placed each year by 100,000 to 300,000, which is similar to the numbers of artificial knee and hip joints placed per year.

    Furthermore, rising prevalence of chronic degenerative diseases and stringent regulations pertaining to sterilization of medical device packaging are the other factors that drive the growth of the medical implant sterile packaging market. However, inappropriate packaging of boxes for medical devices contaminate the devices while transportation and storage causing financial loss thereby, hindering the growth of medical device sterile packaging market.

    Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/995

    Detailed Segmentation:

    By Product Type:

    Clamshell

    Pouches and Bags

    Blisters

    Tubes

    Vials

    Others

    By Application:

    Spinal Implants

    Reconstructive Joint Implants

    Hip Joints

    Knee Joints

    Elbow Joints

    Others

    Extremity Braces and Support

    Knee

    Foot/Ankle

    Hand

    Elbow/Wrist

    Dental Implants

    Cardiovascular Implants

    Others

    By Material Type:

    Plastic

    Paper

    Foils

    Others

    The major players in medical implants sterile packaging market are Beacon, SteriPack, Wipak, Oliver- Tolas, Rexam, Oracle Packaging, Riverside Medical Packaging, West Pharmaceutical Services, Amcor, Rollprint Packaging Products, and Sealed Air Corporation. The key players are focusing on strategic mergers and acquisition and development of innovative packaging systems.

    For instance, Amcor has launched an innovative packaging technology in 2016, known as Fortis sterile breather bag (an uncoated Tyvek header bag), which delivers strength, sustainability, and tear resistance to hold sharp, heavy, and bulky packs in contrast to conventional header bags. Fortis header bags opening allows aseptic removal of contents easier thereby, reduces the risk of contamination to the sterile field.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/995

    Some of the major players involved in global medical implants sterile packaging market are Beacon, SteriPack, Wipak, Oliver- Tolas, Rexam, Oracle Packaging, Riverside Medical Packaging, West Pharmaceutical Services, Amcor, Rollprint Packaging Products, and Sealed Air Corporation.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Hemodynamic Monitoring Systems Market 2017 - Industry Growth, Size, Trends and Forecast to 2025

    Hemodynamics monitoring systems market is expected to gain significant traction over the forecast period, owing to launch of novel monitoring systems by manufacturers. For instance, in 2016, Siemens Healthineers launched a new version of Sensis hemodynamic system at the Annual Scientific Session and Expo of the American College of Cardiology (ACC). Sensis Vibe aids in hemodynamic recording and documentation system in the cardiovascular hybrid operating room (OR) with the new HemoBox signal input unit.

    Non-invasive and minimally invasive monitoring systems are gaining significant traction, as the use of non-invasive technique proves to be beneficial to determine the health condition of the patient and decide whether the patient can benefit from invasive techniques or the monitoring can suffice with the use of non-invasive techniques itself. Manufacturers are therefore, focused towards manufacturing systems that are novel with innovative technologies, in order to maintain their position in the market.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1070

    For instance, in June 2014, Edwards Lifesciences Corporation received U.S. Food and Drug Administration’s (FDA) clearance for its hemodynamic monitoring ClearSight system, which is a non-invasive monitor that provides clinicians access to blood volume and blood flow information for patients at moderate or high risk of post-surgical complications. In March 2017, LiDCO Group Plc introduced its next generation monitor platform in Europe. In addition to the sleek new look, the product has significant improvements in operating system and graphical user interface, and has next version of unity software with added features and functionality. In September 2017, Fysicon received FDA approval for QMAPP hemodynamic monitoring system that features up to 32 bipolar intra-cardiac channels for electrophysiology procedures.

    Market players are focused on expansion of their product portfolio and geographic reach by adoption of inorganic strategies such as mergers and acquisitions, to maintain their positions in the market. For instance, in July 2016, Cheetah Medical signed a supplier agreement with Allina Health, which is a not-for-profit healthcare system that runs hospital network in areas such as Minnesota and western Wisconsin. Through this contract, Cheetah Medical would provide hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network.

    Moreover, in May 2016, LiDCO and ICU Medical signed distribution agreement to sell the LiDCO IM non-invasive hemodynamic monitoring system in U.S. LiDCO IM is a specially configured hemodynamic monitor produced exclusively for ICU Medical that works solely in conjunction with LiDCO’s non-invasive module.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1070

    Detailed Segmentation:

    By Product Type:

    Monitoring Systems

    Disposables

    Probes

    Airflow Sensors

    Others

    By Monitoring Type:

    Invasive Hemodynamics Monitoring

    Non-Invasive Hemodynamic Monitoring

    Minimally Invasive Hemodynamic Monitoring

    By End User:

    Hospitals

    Catheterization Labs

    Ambulatory Surgical Centers

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1070

    Key players are focusing on developing novel and innovative products, to sustain in the hemodynamics monitoring systems market. For instance, in March 2017, Teleflex announced 510(k) clearance by the Food and Drug Administration and both the U.S. and international commercial launch of the Twin-Pass Torque Dual Access Catheter. Moreover, in May 2016, Deltex Medical Group Plc introduced TruFlow in the U.K., which is wider beam, single patient disposable probe, the reconfigured probe tip design that creates a wider ultrasound beam at the focal point in the aorta.

    Key players operating the global hemodynamics monitoring systems market include Edwards Lifescience Corporation, LiDCO Group, Plc, PULSION Medical Systems SE, Cheetah Medical, Inc. ICU Medical, Inc., Deltex Medical Group Plc, and Teleflex, Inc.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Endocrine Testing Market - Industry Growth, Size, Share, Outlook and Forecast 2018-2026

    Companies are launching innovative products to cater the end user need and increase the market footprint in the endocrine testing market. In 2017, Beckman Coulter Diagnostics received FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic (IVD) use. AMH test helps healthcare providers in the assessment of a woman's ovarian reserve, thereby aid in the clinical management of women facing infertility or women planning to become pregnant later in life. The Access AMH assay is a paramagnetic particle chemiluminescent immunoassay for the quantitative determination of AMH levels. The test can be used in conjunction with other clinical and laboratory findings such as antral follicle count, before starting fertility therapy. Companies are also undergoing strategic collaboration to increase market share. For instance, in 2017, Quest diagnostics and Walmart collaborated, under which Quest would open laboratory testing services at 15 Walmart locations initially to gradually increase same.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1755

    Endocrine testing allows profiling of blood concentration of the various endocrine hormone. Over secretion and under secretion of endocrinal hormones results in to development of endocrinal disease. Various endocrinal disease such as hypothyroidism, hyperthyroidism, infertility, polycystic ovarian syndrome, hypo/hyperadrenocorticism, hypogonadism, diabetes, Multiple endocrine neoplasia I and II, Cushing’s disease, Gigantism (acromegaly) and other growth hormone problem and precocious puberty( Early Puberty). Endocrine diseases are caused due to various reasons such as problem in endocrine feedback system, disease condition, and failure of stimulation of glands to release hormones, tumor of an endocrine gland, genetic disorders, infection and physical trauma to an endocrine gland.

    Increasing prevalence of these disease especially hypothyroidism, infertility, and diabetes are expected to drive growth of the global endocrinal testing market. According to study published by Centre for Disease Control and Prevention (CDC), in 2017, around 100 million (30.3 million diabetes and 84.1 million prediabetes) U.S. adults were suffering from diabetes or prediabetes condition. According to American Thyroid Association, 2017, around 12% of U.S. adults are estimated to develop thyroid disease in their lifetime. Postmenopausal osteoporosis caused due to reduced estrogen production after menopause leading to low bone mineral density and increased risk for fracture risks. It is estimated that osteoporosis affects around 10 million American adults annually, 34 million people are at high risk of it due to low bone mass, according to study published by BMC Endocrine Disorder in February 2018.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1755

    Key players are undergoing strategic mergers, acquisitions, and collaborations in order to maintain leading position in market and to tap the new market. In August 2017, North West London Pathology under National Health Service Trust and Abbott Laboratories signed contract worth US$ 252 million under which Abbott Laboratories will supply all analytical equipment and consumables, this contract would manage 26 million tests annually. In 2017, Abbott Laboratories received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. In April 2018, Beckman Coulter launched its Access Sensitive Estradiol assay in the U.S. market, also made available its assay in the most of global markets. This test accurately detects estradiol levels in women, children, and men using low sample. Company also launched Anti-Müllerian Hormone (AMH) assay in 2017, which helps in clinical management of women suffering from infertility. In 2016, company received FDA clearance and commercially launched new Access TSH (3rd IS) assay.

    Key players operating in the endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Beckman Coulter, Inc., Siemens Healthineers, bioMérieux SA, Agilent Technologies, Bi-Rad Laboratories, AB Sciex, F-Hoffmann La Roche AG, Quest Diagnostics, and others.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1755

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Pediatric Nutrition Market - Industry Growth, Size, Share, Trends, and Forecast 2017-2025

    Pediatric nutrition is an important source of nutritional supplement for babies during their formative years. These products are available in milk-based, Soy-based, amino acid-based, and organic forms. These nutritional products support brain development and also helps in the management of allergies and metabolic disorder. Highest number of births are recorded in Asia Pacific, and hence, the region holds maximum opportunity for market players. Due to this, companies such as Mead Johnson Nutrition (acquired by Reckitt Benckiser Group plc), Nestle S.A., and Abbott are trying to maximize their market share in Asia Pacific, especially in China. High return on investments in this market is influencing large players to opt for inorganic methods of growth, as well as increasing the entry of new players in the market. For instance, Reckitt Benckiser Group plc acquired Mead Johnson Nutrition Company in June 2017.

    Lactose intolerance, allergy to cow’s protein milk, maple syrup urine disease, phenylketonuria, and insulin resistance are some of the most common health complications faced by infants and children. These children require special nutrition, which can be provided by nutritional products. Mead Johnson Nutrition (acquired by Reckitt Benckiser Group Plc) developed a separate category of products specifically designed for children suffering from such diseases. These products include Mead Johnson BCAD, for children suffering from maple syrup urine disease and Mead Johnson PhenylFree, for children suffering from phenylketonuria. Other players such as Nestle S.A. and Abbott Laboratories also sell product for children with special needs.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1308

    Increasing number of products to serve this special population coupled with increasing awareness about such diseases is expected to support growth of the global pediatric nutrition market. Furthermore, companies are focusing on development of products that may serve as nutrition enhancer or taste modifier, for the general population. Such products include ChocoMilk and Cal-C-Tose, which when added to milk enhance its nutritional value.

    The four leading players holding a dominant position in the market are Reckitt Benckiser Group Plc, Nestlé S.A., Abbott Laboratories, and Groupe Danone, owing to a spree of market consolidation. Manufacturers are focusing on inorganic growth strategies such as mergers and acquisitions to strengthen their foothold in the global market. For instance, in 2012, Nestle S.A. acquired Pfizer Inc.’s infant nutrition business. In June 2017, Reckitt Benckiser Group Plc acquired Mead Johnson Nutrition, a leading player in pediatric nutrition.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1308

    Moreover, continuous effort from non-government organizations such as WHO, Save The Children, UNICEF and other similar minded organizations to end malnutrition has resulted in formulation of policy that recognizes the importance of nutritional products at very early age, and hence, supports this. For instance, National Nutrition Strategy formulation by Government of India in 2017. These favorable policies is expected to support growth in adoption rate for pediatric nutrition products which in turn will result in growth in the market.

    Companies in the pediatric nutrition market are increasingly focusing on inorganic growth strategies. In 2013, Nestle S.A. acquired U.S.-based Pamlab L.L.C., Covington, La., a medical nutrition company, to broaden its brain health and metabolic health portfolio. Moreover, the company has made strategic investment in companies working on similar product lines. For instance, Nestle S.A. entered into a strategic collaboration with DBV Technologies, to develop a patch-test tool for diagnosis of Cow’s Milk Protein Allergy (CMPA) for infants, in 2016.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1308

    Major players operating in the pediatric nutrition market include Reckitt Benckiser Group Plc, Nestlé S.A., Abbott Laboratories, Groupe Danone, Royal FrieslandCampina, Baxter International Inc., Fresenius Kabi, and B. Braun Melsungen AG

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Enzyme Linked Immunosorbent Assay Market - Industry Growth, Size and Forecast 2017-2025

    According to the National Cancer Institute, cancer has a major impact on the population of U.S. and across the world. The NCI reports approximately 1,685,210 new cases of cancer were diagnosed in 2016. Also, reports demand for efficient detection tests that can be sufficed with the help of ELISA test kits. Moreover, increasing demand for cost-effective diagnostic tool is one of the factor aiding the growth of ELISA market, especially in the low and middle income economies.

    For instance, in October 2017, the Nigerian government and World Health Organization (WHO) launched a campaign to vaccinate around 874,000 people against yellow fever in two states of the country Kwara and Kogi in alliance with the International Coordination Group. The samples of the patients suspected with yellow fever were further tested with the help of ELISA test at the Pasteur Institute in Dakar. However, availability of alternate immunoassays and cross reactivity projected by these tests can hinder the market growth. Development of cost-effective ELISA tests with improved reliability and accuracy can provide potential opportunity for market players to strategize their growth in the global ELISA market.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1505

    Extensive research and development in the field of immunoassay and diagnostics is leading to increasing applications and novel approaches for incorporation of ELISA in various medical fields. This has resulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA) products used in clinical and medical approaches.

    For instance, Inova Diagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, a Calprotectin Extended range of quantitative ELISA assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBD from Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed by Center for Infection and Immunity at University of Columbia in March 2018, extends a window for accurate detection of Zika infection, which is complex with molecular diagnostics procedures.

    The new ZIKV-NS2B-concat ELISA is a faster, less expensive blood test, and clinical tool for accurate detection of Zika from weeks to months after onset of infection facilitating a powerful tool for the clinicians to make quick decisions for their patients. In July 2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administration pre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company's fifth generation HIV diagnostic test that produced efficient diagnostic test results for HIV.

    For instance, in March 2017, Thermo Fisher Scientific, Inc. acquired Core Informatics and added it to analytical Instruments segment to strengthen its existing informatics solutions and bio production offerings. Furthermore, the company players are also focusing on research and development for introducing novel ELISA assays and test kits in to the market to stand out and retain their positions in the market.

    Purchase Copy of This Business Research Report:  https://www.coherentmarketinsights.com/insight/buy-now/1505

    The key players operating in global Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Molecular Diagnostics Market - Industry Insights, Size, Share and Forecast 2017-2025

    Molecular diagnostic test are done for diagnosis and drug discovery & development purpose. Molecular diagnostic test results are quick and accurate, which has led to increasing demand for these. In order to cater to growing demand for such tests, manufacturers are more focused on research & development for new product launches.

    For instance, in February 2017, AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

    Furthermore, in October 2017, FDA approved Roche’s cobas Zika, as first commercially-available donor screening test for Zika virus. In October 2017, QIAGEN launched the custom solution for the molecular diagnostic test, which accelerated adoption of molecular testing for life sciences and molecular diagnostics companies.

    Free Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1545

    In March 2017, Cepheid, Rutgers New Jersey Medical School and FIND announced a new version of the Xpert MTB/RIF test, the Xpert MTB/RIF Ultra (Ultra), for the diagnosis of TB and rifampicin resistance. In August 2017, Selfdiagnostics launched the STD Multitest at MEDICA 2017. STD Multitest is the first and only rapid chlamydia and gonorrhoea duplex disposable molecular test in the world.

    In July 2017, Roche announced commercial availability of the cobas HIV-1/HIV-2 for use on the automated cobas 6800/8800 Systems in countries accepting the CE mark. In July 2017, DiaSorin launched a new CE-IVD molecular diagnostic test, Iam CBFB-MYH11 (not available in the U.S.) for ultra-rapid identification of one of the most common genetic causes of Acute Myeloid Leukemia (AML).Therefore, these increasing product launches in molecular diagnostics is expected to foster growth of the market in the near future.

    Key players in the market are involved in new product launches to cater to increasing demand for molecular diagnostic. For instance, in August 2016 Abbott Laboratories introduced Alinity, a next generation system, used for immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics.

    Some of the other key players in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1545

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Botanical and Plant Derived Drugs Market - Size, Share, Outlook, and Analysis, 2018-2026

    The global botanical and plant derived drugs market is projected to witness significant growth over the forecast period, owing to legalization of medical cannabis. Medical cannabis was legalized in the Czech Republic, in 2013, Argentina and Chile in 2015, and in 2016, marijuana legalization in America reached a tipping point, as the medical marijuana became legal in some of the states.

    Hence, many manufacturers are focused on research and development on medical cannabis to launch new drugs. For instance, one of the drug by GW Pharmaceuticals, Epidiolex consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016.

    Furthermore, increasing number of chronic disease supports the growth of botanical and plant derived drugs, as lung cancer accounts for the leading cause of death in the Eastern, Southern and Southeastern Asia. The region holds for 56% of the world’s population and contributes to 44% of the total cancer cases worldwide according to the statistics mentioned in the Cancer Atlas.

    Free Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1737

    For instance, one of the drug by GW Pharmaceuticals, Epidiolex drug consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016. Moreover, Insys Therapeutics, an America-based company have Subsys drug in their product portfolio, which is prescribed for the treatment of advanced pain associated with cancer. The subsys is a synthetic version of cannabidiol (CBD) and has accounted for almost 100% of the company’s 2014 year-to-date revenue.

    Increasing applications of botanical and plant derived drugs are receiving regulatory approvals with respect to cancer patients - as a cure and as a supplement to current treatments, which provides a great opportunity for conducting clinical trials. For instance, in June 2017, Medlab Clinical received approval to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial. NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage for cancer patients with intractable pain. NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures

    Key players operating in the market include Bayer Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals, Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, and GW Pharmaceuticals.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1737

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Patient Flow Management Solutions Market - Outlook, and Opportunity Analysis, 2018-2026

    Increasing number of hospital admissions and shortage of healthcare professionals is expected to create more burden on the current hospital patient flow management system, thereby increasing the demand for advanced patient flow management solutions.

    A report published by Association of American Medical Colleges (AAMC) in March 2018 focuses on the scenario of shortage of heathcare physicians in both primary and specialty care. This report updates and aligns estimates conducted in 2015, 2016, and 2017, which shows a projected shortage of physicians between 42,600 and 121,300 by 2030.

    The report aggregates the shortages into four broad categories: primary care, medical specialties, surgical specialties, and other specialties. According to this report, an estimated shortfall of between 14,800 and 49,300 primary care physicians will be reported by 2030. Furthermore, for the same period, there will be a shortage in non-primary care specialties between 33,800 and 72,700 physicians.

    Furthermore, key players in the market are focused on acquisition strategies to expand their geographical presence. For instance, in October 2015, Aptean completed the acquisition of Medworxx Solutions Inc. Through the acquisition, Medworxx’s knowledge management, patient flow, and patient safety solutions portfolio for healthcare organizations was added to Aptean’s product portfolio.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/730 

    In May 2018, Allscripts Healthcare Solutions signed a definitive agreement to acquire HealthGrid Holding Company. HealthGrid is a developer of mobile patient engagement platforms, which enable providers to reach patients using existing contact information, without requiring them to sign up for a patient portal. Furthermore, under the agreement, Allscripts will integrate HealthGrid's functions into its FollowMyHealth patient engagement platform.

    In June 2017, Aptean acquired FDM Software. This acquisition enables Aptean to offer an integrated platform with hospital patient flow capabilities. FDM Software operates its business in Records Management (RMS), Computer-Aided Dispatch (CAD), mapping and analysis solutions for public safety agencies in North America and Latin America.

    In July 2018, Change Healthcare received the US$ 5.5 million grant from The Israel Innovation Authority (IIA), to expand its research and development (R&D) facility in Israel.

    In September 2018, Hyland Healthcare and Change Healthcare partnered to offer fully integrated medical claims attachment technology. This allows providers and payers to transmit claims attachment quickly and improves patient experience, optimize the revenue cycle, and reduce inefficiency and wait time.

    Major players operating in the global patient flow management solutions market include Getinge AB, Allscripts Healthcare Solutions, Inc., Cerner Corporation, McKesson Corporation, Epic Systems Corporation, Aptean, Inc., Sonitor Technologies, Inc., Stanley Black & Decker, Inc., and TeleTracking Technologies, Inc.

    Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/730 

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Gastric and Esophageal Cancer Drugs Market - Industry Growth, and Analysis 2018-2026

    Symptoms of gastric and esophageal cancers include difficulty in swallowing (dysphagia), weight loss, chest pain, indigestion or heartburn, coughing or hoarseness, pain behind the breastbone. Early stage of gastric and esophageal cancer does not show any of this signs and symptoms.

    Increasing number of cancer drugs in pipeline studies and rising involvement of key players for development of cancer treatment are expected to propel gastric and esophageal cancer drugs market growth. For instance, in April 2016, Centre Hospitalier Universitaire de Besancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin to determine the maximum tolerated dose (MTD) and recommended doses for phase II (RP2D) by considering the treatment scheme of Dutch study for chemotherapy and radiotherapy. The study is conducted in elderly patients with esophagus cancer. Carboplatin is an anticancer chemotherapy drug from alkylating agent category. The study is estimated to complete by April 2024.

    Free Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2438

    Moreover, in February 2017, Henan Cancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd., initiated Phase 2 exploratory clinical trial to evaluate the efficacy of Apatinib, treatment for advanced esophagus cancer. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2(VEGFR2).

    However, high cost of therapy for the treatment of gastric and esophageal cancers is expected to restraint the market growth. For instance, as per the report published in Healthday, in 2013, cancer patients paid US$ 207,000 a year for the treatment and medications while in 1995 the cost was US$ 54,100 a year.

    For instance, the American Cancer Society’s estimated that about 17,650 new esophageal cancer cases in the U.S. will be diagnosed (13,750 in men and 3,900 in women) by 2019. Moreover, mergers and acquisitions activities by key players in this region are expected to propel the market growth during the forecast period. For instance, in December 2018, GlaxoSmithKline plc announced the acquisition of TESARO Inc, an oncology focused company based in Massachusetts, U.S. This acquisition is expected to strengthen GSK’s pharmaceutical business by accelerating GSK’s pipeline and commercial capability in oncology.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2438

    Key players in Europe are focused on various business strategies such as acquisitions and mergers, which in turn boosts growth of the market. For instance, in September 2018, Boehringer Ingelheim acquired all shares of ViraTherapeutics, an Austria-based biopharmaceutical company, specializing in the development of oncolytic viral therapies. The total transaction value for this acquisition was US$ 240.52 million. This acquisition strengthened Boehringer Ingelheim’s commitment to research and development for viral-based immuno-oncology treatment.

    Key players for gastric and esophageal cancer drugs market includes Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co. and others.

    Purchase this Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2438

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Hemorrhoid Treatment Devices Market Industry Report, Size, Share, and Analysis, 2018-2026

    Hemorrhoid is a common disease in a general population, which is also known as the piles, where the patient suffers from painless bleeding during bowel movement, itching and irritation in anal side, swelling of anal veins, pain and discomfort, and formation of lumps near to anus, which is sensitive and painful. Hemorrhoid is distinguished into two parts such as internal hemorrhoid and external hemorrhoid.

    Treatment for hemorrhoid disease includes non-surgical treatment and surgical treatment. Non-surgical treatment includes laxatives and corticosteroids. Surgical treatment includes banding, sclerotherapy, infrared coagulation, hemorrhoidectomy, and hemorrhoid sampling. Various devices are used for the treatment of hemorrhoid such as endoscopic rubber band ligator, hemorrhoidal multi-band ligator, disposable hemorrhoid banding system, mcgivney hemorrhoidal ligator, endoscopic infrared coagulator, and lumatec infrared coagulator.

    New product launches is expected to drive the global hemorrhoid treatment devices market size. For instance, in March 2019, De Scalene launched a new device called Cryocure, an affordable device to treat hemorrhoid without surgery. Cryocure helps to stop the bleeding from anal blood vessels and constriction of that anal blood vessels.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2647

    Furthermore, increasing incidence and prevalence of hemorrhoid disease in the U.S. is expected to drive the global hemorrhoid treatment devices market growth. For instance, in March 2016, according to the National Center for Biotechnology Information (NCBI), overall prevalence of hemorrhoid disease in the general population is around 4.4% and self-reported incidence of hemorrhoid disease is around 10 million persons, annually in the U.S.

    For instance, in January 2018, PRIVI MEDICAL PTE. LTD., received U.S. FDA clearance for its new device (Instalief), which is used for the hemorrhoid treatment. Instalief is the drug-free device, which provides the instant cold relief without any side-effects.

    Majority of market players in the global hemorrhoid treatment devices market such as Zhengzhou Safute Electronic Equipment Co., Ltd., and Wuxi Shenkang Medical Instrument Equipment Co. Ltd belong to China. These companies include various hemorrhoid treatment devices such as anorectal physical therapy device, SAFUTE hemorrhoid surgery device, and sigmoid colon and hemorrhoid disease treating device.

    Key players operating in the global hemorrhoid treatment device market include Johnson & Johnson, PRIVI MEDICAL PTE. LTD., Cook Medical, Medtronic Plc, Integra LifeSciences Corporation, OBP Medical Corporation, Boston Scientific Corporation, Sklar Surgical Instruments, Surkon Medical Co., Ltd., and CONMED Corporation.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2647

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Halitosis Treatment Market - Size, Share, Trends, and Forecast 2018-2026

    Halitosis or bad breath according to a National Center for Biotechnology Information (NCBI), affect half of the population in the U.S. and between 50% and 60% of the population in France. Although it occurs due to number of causes, oral hygiene is a major factor. Respiratory system problems, hepatic disease, gastrointestinal disease, hematological or endocrine system disorders, and metabolic conditions can also the cause halitosis.

    Other potential factors that contribute to halitosis are endodontic, surgical, and pathologic factors such as exposed tooth pulps and non-vital tooth with fistula draining into the mouth, oral cancer, oral cavity pathologies, and ulcerations, extractions/healing wounds or prosthetics. All these factors cause food or plaque retention area, decay of amino acids, raising bacterial amount, tissue breakdown, and decreasing of saliva flow. These conditions result in the release of volatile compounds causing halitosis.

    Treatment for bad breath can vary depending on the cause. For instance, halitosis caused due to a buildup of bacteria (plaque) on teeth can be treated with mouth rinse that kills the bacteria. Furthermore, halitosis caused due to gum diseases can be treated with tooth cleaning procedures.

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2219

    Manufacturers in halitosis treatment market are focused on development and approval of new products and strategic collaborations with other industry players to gain significant market share. For instance, in 2017, Listerine, a leading market player in halitosis treatment market launched a new Green Tea variant that combines essential oils and green tea extract with fluoride.

    Increasing consumption of tobacco and alcohol, medical condition such as tonsils and inflammation of nose, throat or sinuses and metabolic diseases are the major factors driving the halitosis treatment market growth. According to the National Center for Biotechnology Information (NCBI) 2013 study, halitosis is very common and affects around 50% of the general population around the world.

    Although halitosis has multifactorial origins, around 90% cases occur due to oral cavity such as poor oral hygiene, tongue coat, periodontal disease, unclean dentures, food impaction, oral carcinomas, faulty restorations, and throat infections. Treatment of halitosis is very important, as it can cause serious conditions such as stress. According to the Bad Breath Institute 2018 study, people with halitosis are 60% more likely to suffer from stress, while 57% of bad breath sufferers report feelings of depression due to their condition. However, lack of awareness among the under developed regions can confine the halitosis treatment market growth.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2219

    Key players operating in the global halitosis treatment market include Abbott Laboratories, AstraZeneca Plc., Colgate-Palmolive Company, Dr. Harold Katz, Listerine, and Rowpar Pharmaceuticals.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Surgical and Dental Loupes Market Size, Growth | Industry Analysis, 2018-2026

    The surgical and dental loupes market growth is driven by increasing prevalence of dental problems. According to FDI World Dental Federation’s Oral Health Atlas Published in 2015, oral disease affects around 3.9 billion people worldwide, with untreated tooth decay, which impacts around 44% of world’s population. Moreover, 90% of tooth decay cases require endodontic procedures that involves surgical procedure to save the natural tooth. Rising incidence of musculoskeletal disorders related to dental anatomy and increasing utilization of restorative dentistry and endodontic practices by the utilization of dental loupes drives growth of the surgical and dental loupes market. In addition, increasing dental insurance coverage and rising number of dental procedures drives growth of the surgical and dental loupes market.

    Moreover, manufacturers and researchers are entering into partnerships, which include the agreement that allow dentists to improve patient care. For instance, in June 2013, Carl Zeiss Meditec Inc. and Henry Schein Dental announced their distribution partnership in the U.S. for ZEISS EyeMag dental loupes. This partnership facilitates the U.S. dentists to easily incorporate practice premium dental loupes for improved patient care. According to the World Health Organization’s Oral Health factsheet in 2018, the world prevalence of traumatic dental injuries in the arrangement of teeth in a particular individual is around 20%. Oral dental trauma can be caused by oral and environmental factors (unsafe playgrounds and schools).

    Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2771

    Geriatric population with dental problems is another major factor driving growth of the market, as they face oral health issues such as shrinkage of gums with age, leading to tooth decay or infection, loss of teeth, and poor fitting dentures. According to WHO oral health factsheet 2012, around 30% of people aged 65–74 years have no natural teeth and burden is expected to increase in the near future.

    Moreover, in November 2016, Orascoptic, a leader in superior vision solutions for dental and medical professionals, launched HDL 2.5 Micro- a 2.5x magnification power Galilean loupe with high definition resolution and substantial field of view.

    Rising healthcare expenditure, technological advancements, and increasing incidence of dental disorders in the region. According to the Centers for Disease Control and Prevention, in 2015, over 1 in 4 or 27% adults in the U.S. had untreated tooth decay. Moreover, at the 2014 Greater New York Dental Meeting in the U.S., Orascoptic launched RDH Elite loupe, which is designed with a singular focus on dental hygiene.

    Some of the key players operating in the global surgical and dental loupes market include Univet Optical Technologies, L.A. Lens, Rose Micro Solutions, Ergonoptix, Designs For Vision, PeriOptix, Enova Illumination, SheerVision Incorporated, Carl Zeiss Meditec AG, Orascoptic, and SurgiTel.

    Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2771

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah
    Coherent Market Insights
    1001 4th Ave, 
    #3200 
    Seattle, WA 98154
    Tel: +1-206-701-6702
    Email: sales@coherentmarketinsights.com


  • Healthcare Simulators Market Size, Trend and Forecast Till 2026

    The rising launch of high-fidelity simulators which provide the most realistic experience by the developers is a major factor propelling market growth. For instance, in February 2018, MedaPhor launched BodyWorks Eve, a high-fidelity female manikin-based simulator that can be used by medical professionals to meet educational requirements. The Point of Care Ultrasound (PoCUS) simulator can be used across emergency medicine and critical care.

    Moreover, increasing healthcare expenditure is also expected to boost adoption of medical simulators. The healthcare spending will improve quality of the healthcare services, aid in employing more practitioners, and better medical training and developed infrastructure with advanced software. For instance, according to World Health Organization, China’s healthcare market reached US$ 853.7 billion in 2016, an increase of 12% in local currency, the number projected to reach $1.1 trillion by 2020.

    Free Request Sample Copy of This Report: www.coherentmarketinsights.com/insight/request-sample/2802

    Manufacturers in the Global Healthcare Simulators market are focusing on strategic mergers and acquisitions in order to gain significant market share. For instance, in August 2014, 3D Systems acquired Simbionix which was the global leader in 3D virtual reality surgical simulation and training. This technology by Simbionix was complementary with 3D System’s product offering.

    Furthermore, the web-based simulation programs provide a valuable resource as they can be combined with classroom teaching, thereby facilitating the development of students’ clinical competence. Thus, increasing demand for web-based simulation is directly associated with the increasing number of medical institutes for providing students with clinical placement experience, especially in the field of medicine and nursing.

    However, simulators cannot mimic human systems completely. The complexity and diversity of human systems is very high and difficult to be mimicked by instruments or software, providing the inadequate information as compared to human response. Moreover, medical stimulators require technically trained professionals to guide through the learning process involved in simulation-based medical education. All such factors are expected to negatively impact the market growth over the forecast period.

    Moreover, manufacturers are launching new products in regular intervals with new technology and increasing fidelity, which is fuelling the market growth over the forecast period. For instance, in May 2018, SimMan Vascular System was developed by Laerdal Medical, in collaboration with Mentice. It includes Mentice VIST technology and is largely adopted in pre- and in-hospital team training to support acute endovascular procedures.

    Get PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/2802

    Major players operating in the global healthcare simulators market include, Laerdal Medical, 3D Systems, Simulab Corporation, Simulaids, Inc., Kyoto Kagaku, Mentice, Medaphor, CAE Healthcare, Gaumard Scientific Company, Limbs & Things, BT, Inc., Trandomed 3D, Inc., Fujian Zhongli Co., Ltd., and Tellyes Scientific Co., Ltd.

    About Us:

    Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

    Contact Us:

    Mr. Shah

    Coherent Market Insights

    1001 4th Ave,

    #3200

    Seattle, WA 98154

    Tel: +1-206-701-6702

    Email: sales@coherentmarketinsights.com


connect